On 20 Nov 2025, Shree Ganesh Biotech India recorded a day change of -1.47%, contrasting with the Sensex’s positive movement of 0.20%. This decline extends a three-day losing streak during which the stock has returned -4.29%. The company’s share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating persistent weakness in market sentiment.
Over the past week, the stock has shown a return of -6.94%, while the Sensex gained 1.04%. The one-month performance reveals a -9.46% return for Shree Ganesh Biotech India, compared to the Sensex’s 1.18%. The three-month period further emphasises the stock’s underperformance with a -15.19% return against the Sensex’s 4.28%. Yearly figures highlight a more pronounced disparity: the stock has returned -37.38% over the last 12 months, whereas the Sensex has recorded a 10.03% gain.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Longer-term performance data further illustrates the stock’s challenges. Over three years, Shree Ganesh Biotech India has returned -63.78%, while the Sensex has appreciated by 38.43%. The five-year figures show a stark contrast with the stock at -86.65% and the Sensex at 94.52%. Over a decade, the stock has remained flat at 0.00%, whereas the Sensex has surged by 229.98%.
From a financial perspective, the company’s recent results for the nine-month period ending September 2025 reveal a contraction in net sales to Rs.5.16 crores, reflecting a decline of 44.64%. The net profit after tax (PAT) for the same period stands at a loss of Rs.0.61 crores, also showing a reduction of 44.64%. The debtors turnover ratio for the half-year is recorded at 0.00 times, indicating potential issues in receivables management.
Shree Ganesh Biotech India operates within the Pharmaceuticals & Biotechnology sector, classified as a microcap company. The stock’s valuation appears risky relative to its historical averages, with earnings before interest, taxes, depreciation, and amortisation (EBITDA) showing negative figures. The company’s ability to service debt is constrained, with an average EBIT to interest ratio of 0.91, signalling limited coverage of interest obligations.
Profitability metrics also highlight subdued returns. The average return on equity (ROE) stands at 2.62%, indicating modest profitability relative to shareholders’ funds. These financial indicators align with the stock’s prolonged underperformance and the downward pressure on its market valuation.
Considering Shree Ganesh Biotech India ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
The stock’s ownership structure is dominated by non-institutional shareholders, which may influence liquidity and trading dynamics. The company’s market capitalisation remains within the microcap segment, reflecting its relatively small size in the broader market context.
In summary, Shree Ganesh Biotech India’s stock has reached an unprecedented low of Rs.0.66, underscoring a sustained period of decline across multiple time horizons. The company’s financial data for recent periods reveals contraction in sales and profitability, alongside challenges in debt servicing and receivables turnover. These factors collectively contribute to the stock’s current valuation and market position within the Pharmaceuticals & Biotechnology sector.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
